TY - JOUR
T1 - Mutant IDH1 differently affects redox state and metabolism in glial cells of normal and tumor origin
AU - Biedermann, Julia
AU - Preussler, Matthias
AU - Conde, Marina
AU - Peitzsch, Mirko
AU - Richter, Susan
AU - Wiedemuth, Ralf
AU - Abou‐el‐ardat, Khalil
AU - Krüger, Alexander
AU - Meinhardt, Matthias
AU - Schackert, Gabriele
AU - Leenders, William P.
AU - Herold‐mende, Christel
AU - Niclou, Simone P.
AU - Bjerkvig, Rolf
AU - Eisenhofer, Graeme
AU - Temme, Achim
AU - Seifert, Michael
AU - Kunz‐schughart, Leoni A.
AU - Schröck, Evelin
AU - Klink, Barbara
N1 - Funding Information:
This work was supported by the Else Kr?ner?Fresenius?Stiftung (EKFS) (Else Kr?ner? Promotionskolleg Dresden), the Free State of Saxony and European Social Fund of the European Union (ESF).
Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/12
Y1 - 2019/12
N2 - IDH1R132H (isocitrate dehydrogenase 1) mutations play a key role in the development of low‐grade gliomas. IDH1wt converts isocitrate to α‐ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+), whereas IDH1R132H uses α‐ketoglutarate and NADPH to generate the oncometabolite 2‐hydroxyglutarate (2‐HG). While the effects of 2‐HG have been the subject of intense research, the 2‐HG independent effects of IDH1R132H are still ambiguous. The present study demonstrates that IDH1R132H expression but not 2‐HG alone leads to significantly decreased tricarboxylic acid (TCA) cycle metabolites, reduced proliferation, and enhanced sensitivity to irradiation in both glioblastoma cells and astrocytes in vitro. Glioblastoma cells, but not astrocytes, showed decreased NADPH and NAD+ levels upon IDH1R132H transduction. However, in astrocytes IDH1R132H led to elevated expression of the NAD‐synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT). These effects were not 2‐HG mediated. This suggests that IDH1R132H cells utilize NAD+ to restore NADP pools, which only astrocytes could compensate via induction of NAMPT. We found that the expression of NAMPT is lower in patient‐derived IDH1‐ mutant glioma cells and xenografts compared to IDH1‐wildtype models. The Cancer Genome Atlas (TCGA) data analysis confirmed lower NAMPT expression in IDH1‐mutant versus IDH1‐wildtype gliomas. We show that the IDH1 mutation directly affects the energy homeostasis and redox state in a cell‐type dependent manner. Targeting the impairments in metabolism and redox state might open up new avenues for treating IDH1‐mutant gliomas.
AB - IDH1R132H (isocitrate dehydrogenase 1) mutations play a key role in the development of low‐grade gliomas. IDH1wt converts isocitrate to α‐ketoglutarate while reducing nicotinamide adenine dinucleotide phosphate (NADP+), whereas IDH1R132H uses α‐ketoglutarate and NADPH to generate the oncometabolite 2‐hydroxyglutarate (2‐HG). While the effects of 2‐HG have been the subject of intense research, the 2‐HG independent effects of IDH1R132H are still ambiguous. The present study demonstrates that IDH1R132H expression but not 2‐HG alone leads to significantly decreased tricarboxylic acid (TCA) cycle metabolites, reduced proliferation, and enhanced sensitivity to irradiation in both glioblastoma cells and astrocytes in vitro. Glioblastoma cells, but not astrocytes, showed decreased NADPH and NAD+ levels upon IDH1R132H transduction. However, in astrocytes IDH1R132H led to elevated expression of the NAD‐synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT). These effects were not 2‐HG mediated. This suggests that IDH1R132H cells utilize NAD+ to restore NADP pools, which only astrocytes could compensate via induction of NAMPT. We found that the expression of NAMPT is lower in patient‐derived IDH1‐ mutant glioma cells and xenografts compared to IDH1‐wildtype models. The Cancer Genome Atlas (TCGA) data analysis confirmed lower NAMPT expression in IDH1‐mutant versus IDH1‐wildtype gliomas. We show that the IDH1 mutation directly affects the energy homeostasis and redox state in a cell‐type dependent manner. Targeting the impairments in metabolism and redox state might open up new avenues for treating IDH1‐mutant gliomas.
KW - Glioma
KW - IDH1
KW - IDH‐mutation
KW - Metabolism
KW - NAD‐synthesis
KW - Redox state
UR - http://www.scopus.com/inward/record.url?scp=85077268551&partnerID=8YFLogxK
U2 - 10.3390/cancers11122028
DO - 10.3390/cancers11122028
M3 - Article
C2 - 31888244
AN - SCOPUS:85077268551
SN - 2072-6694
VL - 11
JO - Cancers
JF - Cancers
IS - 12
M1 - 2028
ER -